Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

IOM Finds No Link Between Silicone Implants and Cancer

August 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

WASHINGTON-An extensive review of the medical literature finds that women with silicone breast implants are no more likely to develop cancer and several other major ailments than women in the general population. The new report by the Institute of Medicine (IOM) concludes, however, that implants commonly lead to often-painful complications that may require surgery or other treatment.

WASHINGTON—An extensive review of the medical literature finds that women with silicone breast implants are no more likely to develop cancer and several other major ailments than women in the general population. The new report by the Institute of Medicine (IOM) concludes, however, that implants commonly lead to often-painful complications that may require surgery or other treatment.

“Based on all the evidence, we determined that the primary safety concern associated with breast implants is local complications resulting in pain, disfigurement, infections, and other medical problems,” said Stuart Bondurant, MD, who chaired the committee that prepared the report. “We could find no definite evidence linking breast implants to cancer, immunologic diseases, neurologic problems, or other systemic diseases.”

The Department of Health and Human Services funded the report, “Safety of Silicone Breast Implants,” as directed by Congress.

To complete its report, the committee evaluated more than 3,000 publications, including some 2,000 peer-reviewed articles. It is the third by a scientific panel to conclude that current evidence does not support a causal link between silicone breast implants and serious diseases such as cancer. The others were done by the UK’s Independent Review Group, released in 1998, and the National Science Panel, appointed by federal judge Sam C. Pointer, Jr., who is handling the lawsuits against implant makers that have been consolidated by the federal courts.

The issue of breast implants has been a contentious and controversial one for years. “The IOM excluded anyone from its committee who had participated in studies of breast implants, whose associations or prior statements might bias the results, who was involved with implant makers or relevant ongoing legal matters, or who had conflicts of interest,” said Dr. Bondurant, professor of medicine and dean emeritus of the University of North Carolina School of Medicine.

Problems With Mammograms

The IOM panel cautioned that implants can make it harder to detect breast cancer on mammograms “by obscuring a variable part of the breast tissue, distorting breast architecture, and especially in the presence of firm contractures, making a proper examination with proper compression of the breast more difficult and occasionally impossible.”

The committee also concluded that there is no evidence that mothers with implants pass on silicone to their infants when breast-feeding. Indeed, the panel noted, higher levels of silicon, the parent element of silicone, have been detected in cows’ milk and commercial baby formula than in the milk of nursing mothers with implants.

As for the relatively common local complications, such as implant rupture, contraction, and deflation, the panel found it difficult “to come up with a precise estimate of the frequencies of these outcomes in the absence of large, long-term, systematic follow-up studies,” said vice chair Virginia L. Ernster, PhD, of the University of California, San Francisco.

In its section on cancer, the panel concluded that the available evidence fails to support an association of silicone or silicone breast implants with experimental carcinogenesis (other than rodent solid-state carcinogenesis), primary, or recurrent breast cancer, breast sarcoma, or other solid tumors, lymphoma, or myeloma.

“If anything, evidence (though limited) suggests a lower risk of breast cancer in women with silicone breast implants,” the report said. At a press conference, Dr. Bondurant hastened to emphasize that the report did not mean to imply any protective effect of silicone implants.

The panel’s review also failed to substantiate reported links between implants and a recurrence of breast cancer or an association with increased risk of sarcomas, monoclonal gammopathy of undetermined significance, and immunoglobulin G myeloma.

Articles in this issue

False positives frequent in CT lung cancer screening trial
Stereotactic Core Biopsy Establishes Many Prognostic Factors
Breast Cancer Prevention With Tamoxifen Appears Cost-Effective
NCI Discovers Gene Variations From Existing Databases
CPDR Unveils First Center Solely for Prostate Cancer Research
Going Beyond CHOP in Advanced Large-Cell Lymphoma
Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilion
Ernst Wynder, Pioneer in Preventive Medicine
AHCPR Plans Health Care Market, Managed Care Research Centers
NSAIDs May Protect Against Common GI Cancers
Four Researchers Receive General Motors Awards
Anal Condylomata More Threatening in HIV+ Patients
IOM Finds No Link Between Silicone Implants and Cancer
IL-12 Gene Therapy Inhibits Osteosarcoma Lung Mets in Mice
Law May Play an Important Role in End of Life Decisions
Recent Videos
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Advertisement

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.


Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Related Content
Advertisement

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.


Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.